会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Indolopyrrolocarbazole derivatives and antitumor agents
    • 吲哚吡咯咔唑衍生物和抗肿瘤剂
    • US06703373B1
    • 2004-03-09
    • US10070825
    • 2002-03-11
    • Katsuhisa KojiriHisao KondoHiroharu ArakawaMitsuru OhkuboHiroyuki Suda
    • Katsuhisa KojiriHisao KondoHiroharu ArakawaMitsuru OhkuboHiroyuki Suda
    • A01N4304
    • C07H19/00C07H15/00C07H19/22
    • A compound represented by the formula or a pharmaceutically acceptable salt thereof wherein R represents an unsubstituted pyridyl, furyl or thienyl group, or a pyridyl, furyl or thienyl group each of which has one or more substituents selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group except that when the pyridyl, furyl or thienyl group has a lower alkoxy group as a substituent, each of which simultaneously has another substituent selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group, m represents an integer of 1 to 3, and G represents a &bgr;-D-glucopyranosyl group, and the positions of substitution of the hydroxyl groups on the indolopyrrolocarbazole ring are the 1- and 11-positions, or the 2- and 10-positions, and an antitumore agent containing it as an effective ingredient. The compounds have a better antitumor action than known compounds having a similar structure.
    • 由下式表示的化合物或其药学上可接受的盐,其中R表示未取代的吡啶基,呋喃基或噻吩基,或吡啶基,呋喃基或噻吩基,其各自具有一个或多个选自羟基, 低级烷氧基,羟基低级烷基和羟基低级烯基,不同之处在于当吡啶基,呋喃基或噻吩基具有低级烷氧基作为取代基时,其各自同时具有选自羟基的另一取代基 ,低级烷氧基,羟基低级烷基和羟基低级烯基,m表示1〜3的整数,G表示β-D-吡喃葡萄糖基,吲哚并吡咯并唑的羟基取代位置 环是1-和11位,或2-和10-位,以及含有它作为有效成分的抗肿瘤剂。化合物具有更好的抗肿瘤 比已知具有相似结构的化合物。
    • 10. 发明授权
    • Indolopyrrolocarbazole derivatives
    • 吲哚并吡咯并咔唑衍生物
    • US5668271A
    • 1997-09-16
    • US474659
    • 1995-06-07
    • Katsuhisa KojiriHisao KondoHiroharu ArakawaMitsuru OhkuboHiroyuki Suda
    • Katsuhisa KojiriHisao KondoHiroharu ArakawaMitsuru OhkuboHiroyuki Suda
    • C07H19/044C07H19/23C07D273/00
    • C07H19/044
    • Indolopyrrocarbazole derivatives represented by formula (I) and the pharmaceutically acceptable salts thereof have excellent antitumor activity as evidenced by their in vitro proliferation inhibiting activity against mouse leukemia cell, human gastric cancer cell, human lung cancer cell and human colon cancer cell, ##STR1## wherein R.sup.1 and R.sup.2 independently represent, for example, a hydrogen atom or various hydrocarbon groups which may be substituted or heterocyclic groups which may also be substituted; or a group --Y--R.sup.3 where Y represents a carbonyl group, thiocarbonyl group or sulfonyl group and R.sup.3 represents a hydrogen atom or one of various aliphatic, cycloaliphatic, aryl, nitrogen-containing (e.g. amino, hydrazino, etc) or heterocyclic groups, which groups may be substituted by various substituents; or R.sup.1 and R.sup.2 may combine to represent a lower alkylidene group which may be substituted; or R.sup.1 and R.sup.2, together with the N-atom to which they are bonded form a heterocyclic group which may be substituted;G represents a pentose or hexose group; and X.sup.1 and X.sup.2, independently, represent, for example, hydrogen, halogen, amino, hydroxyl, alkoxy, aryloxy, carboxyl, alkoxycarbonyl or alkyl. These compounds have improved water solubility as compared to rebeccamycin.
    • 由式(I)表示的吲哚并吡咔唑衍生物及其药学上可接受的盐具有优异的抗肿瘤活性,如通过其对小鼠白血病细胞,人胃癌细胞,人肺癌细胞和人结肠癌细胞的体外增殖抑制活性所证明的。 其中R1和R2独立地表示例如氢原子或可以是取代的各种烃基或也可以被取代的杂环基; 或其中Y表示羰基,硫代羰基或磺酰基且R 3表示氢原子或各种脂族,脂环族,芳基,含氮(例如氨基,肼基等)或杂环基之一的基团-Y-R3, 哪些基团可以被各种取代基取代; 或者R 1和R 2可以组合以表示可被取代的低级亚烷基; 或R 1和R 2与它们所键合的N-原子一起形成可被取代的杂环基; G表示戊糖或己糖基团; X 1和X 2独立地表示例如氢,卤素,氨基,羟基,烷氧基,芳氧基,羧基,烷氧基羰基或烷基。 与雷贝卡霉素相比,这些化合物具有改善的水溶性。